Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer

Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). BCG immunotherapy prevents disease recurrence and progression to...

Full description

Bibliographic Details
Main Authors: Hyung Suk Kim, Ho Kyung Seo
Format: Article
Language:English
Published: Korean Urological Association 2021-07-01
Series:Investigative and Clinical Urology
Subjects:
antibody-drug conjugate
bacillus calmette-guerin
immune checkpoint inhibitors
oncolytic virotherapy
urinary bladder neoplasms
Online Access:https://www.icurology.org/pdf/10.4111/icu.20200602

Internet

https://www.icurology.org/pdf/10.4111/icu.20200602

Similar Items